New Discovery Could Give Scientists a Way to Destroy Cancer Cells

Human trials may be a long way off, but this is a huge step forward.

10. 24. 16 by Jess Vilvestre
Victo Ngai
Image by Victo Ngai

Cells That Avoid Death

A new compound, discovered by international pharmaceutical companies Servier and Vernalis (R&D), has the potential to prevent several kinds of cancers that afflict humans.

The study, published in Nature, notes that cancers manifest in the abnormal and harmful growth of cells in the body. Cancer cells are particularly resilient because they can avoid apoptosis—a cell mechanism that regulates the rate of cell division, in which cell masses that are no longer needed commit suicide. Cancer cells avoid this by possessing a protein called myeloid cell leukemia 1 (MCL1).

“MCL1 is important for many cancers because it is a pro-survival protein that allows the cancerous cells to evade the process of programmed cell death that normally removes cancer cells from the body,” said Guillaume Lessene of Walter and Eliza Hall Institute, one of the study’s partner industries.

The researchers propose to resolve this using a compound called S63845, a molecule synthesized by Servier. “Extensive studies performed in a variety of cancer models have shown that S63845 potently targets cancer cells dependent on MCL1 for their survival,” said Lessene. Essentially, use this to block the protein, and cancer can’t grow.


Cancer-Free Tomorrows

Lessene’s research group, together with hematologists from The Alfred Hospital and Servier scientists, demonstrated that the compound was effective against several cancer types, including acute myeloid leukemia, lymphoma and multiple myeloma, as well as solid cancers such as melanoma and cancers of the lung and breast. They also report that S63845 can be administered to patients in doses that can be tolerated by normal cells.

Lessene believes that the study drives forward previous research on how cancers survive, and how to treat them. S63845 is a member of a new class of of anti-cancer drugs called BH3 mimetics. “BH3 mimetics inhibit a group of proteins known as the ‘pro-survival BCL-2 proteins’. MCL1 is a member of this protein family,” he said.

The study is in its early stages and probably won’t be tested on people soon, but it’s another step towards securing a better future safe from cancer.

Care about supporting clean energy adoption? Find out how much money (and planet!) you could save by switching to solar power at By signing up through this link, may receive a small commission.


Share This Article

Keep up.
Subscribe to our daily newsletter to keep in touch with the subjects shaping our future.
I understand and agree that registration on or use of this site constitutes agreement to its User Agreement and Privacy Policy


Copyright ©, Camden Media Inc All Rights Reserved. See our User Agreement, Privacy Policy and Data Use Policy. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with prior written permission of Futurism. Fonts by Typekit and Monotype.